Graves’ disease in children in the two decades following implementation of an iodine prophylaxis programme

ADA BOROWIEC, DOMINIKA LABOCHKA, MONIKA MILCZAREK, MONIKA KOPIEC-BURDECKA, DOROTA ARTEMNIAK-WOJTOWICZ, BEATA PYRŻAK, ANNA M. KUCHARSKA

Department of Paediatrics and Endocrinology, Medical University of Warsaw, Warsaw, Poland

Abstract
Grave’s disease (GD) is a form of thyroid autoimmune disease characterised by hyperthyroidism. It is a rare clinical problem in paediatrics. Development of disease is the result of genetic susceptibility and some environmental factors. One of the best-documented environmental factors involved in thyroid autoimmunity is iodine excess. The aim of our study was to analyse the clinical course and response to pharmacological treatment in children diagnosed with Graves’ disease in first two decades after mandatory salt iodination. Records of 94 children diagnosed with GD in the years 1998-2017 were analysed. Medical data of patients was compared between two decades following implementation of iodine prophylaxis: 1998-2007 (first-decade group – FDG) and 2008-2017 (second-decade group – sDG); 34 and 60 patients, respectively. Medical data of FDG was obtained from archival records and previous analysis performed in 2006. Data of 60 patients from sDG were obtained from currently available medical records. Results were statistically analysed using Microsoft Excel and Statistica 11 software. Results: In our study, after mandatory salt iodination, the tendency of an increase in newly diagnosed GD in children without family susceptibility was observed. The antibody profile indicates the significant contribution of the autoimmune process involving all thyroid antigens; therefore, the term “autoimmune hyperthyroidism” seems to be more appropriate than classical GD in this group of patients. The first-choice treatment with methimazole rarely causes adverse events during the therapy, and they have benign character.

Key words: children, Graves’ disease, clinical course, salt iodination.

Introduction
Grave’s disease (GD) is a form of thyroid autoimmune disease characterised by hyperthyroidism. It is a rare clinical problem in paediatrics, and the incidence is estimated at 0.1-3 per 10,000 children [1]. On the other hand, it is the most common cause of thyrotoxicosis in developmental age [1]. GD in prepubertal children is less common, but its course is usually more severe and more often requires radical therapy [2]. Development of disease is the result of genetic susceptibility and some environmental factors. Genetic predisposition is usually multifactorial, but some monogenic diseases are also associated with increased risk of GD, such as 21 trisomy [3, 4], Turner syndrome [5], or DiGeorge syndrome [6]. One of the best documented environmental factors involved in thyroid autoimmunity is iodine excess [7]. Increased incidence of autoimmune thyroid diseases was observed in countries after the introduction of iodine prophylaxis [8-10]. Higher incidence was noted after iodine fortification of salt, and it concerns especially young subjects with a genetic predisposition [11].

In Poland, mandatory salt iodination was introduced in 1997. Table salt is obligatorily enriched in iodine 30 ±10 mg KJ/1 kg NaCl [12]. Studies performed 10 years after introducing iodination classified Poland’s status as iodine-sufficient in the general population [13].

The aim of our study was to analyse the clinical course and the response to pharmacological treatment in children diagnosed in our centre with Graves’ disease in the first two decades after mandatory salt iodination.

Material and methods
We analysed retrospectively the records of 94 children diagnosed with GD in the Department of Paediatrics and Endocrinology, Medical University of Warsaw, in the...
years 1998-2017. The diagnosis was established on the basis of clinical symptoms of hyperthyroidism and confirmed by hormonal tests and the presence of TSH receptor antibodies (TRAb). Clinical and biochemical features were analysed at diagnosis: age at onset, the most common symptoms and complaints, biochemical abnormalities in laboratory test, anti-thyroid antibodies, and thyroid ultrasound. The response to antithyroid drug therapy and its side effects were assessed. Medical data of patients were compared between two decades following implementation of an iodine prophylaxis programme in Poland in the periods 1998-2007 (first-decade group – FDG) and 2008-2017 (second-decade group – SDG); 34 and 60 patients, respectively. Medical data of FDG was obtained from archival records and previous analysis performed in 2006 [14]. Data of 60 patients from SDG were obtained from currently available medical records.

Free thyroxine (fT\textsubscript{4}, normal range: 0.78-1.31 ng/dl) and triiodothyronine (fT\textsubscript{3}, normal range: 2.33-4.35 pg/ml), thyroid stimulating hormone (TSH, normal range: 0.53-3.59 µIU/ml), anti-thyroid peroxidase antibodies (anti-TPOAb, normal range < 5.6 IU/ml), and anti-thyroglobulin antibodies (anti-TGAb, normal range < 4.1 IU/ml) were evaluated by chemiluminescence immunoassay (Architect i1000SR, Germany). The value of TSH receptor antibodies (TRAb) was measured by electrochemiluminescence immunoassay (Cobas e601, Roche); a positive value was considered as > 1.75 IU/l. Thyroid ultrasound was performed in each patient at the time of diagnosis. Results were statistically analysed using Microsoft Excel software and reported as mean and standard deviation, median, maximal, and minimal values. Comparisons between groups was conducted using the Independent Samples T-test performed with Statistica 11 software. A \( p \)-value < 0.05 was considered statistically significant.

### Results

#### Clinical features of Graves’ disease at diagnosis

The symptoms at diagnosis were characteristic for hyperthyroidism and did not differ in FDG and SDG children. The most common clinical feature at diagnosis observed in children from SDG was tachycardia (Table 1), in four cases accompanied by cardiac arrhythmia, and in one case cardiac arrhythmia was not connected with tachycardia. The most frequent complaints were fine, wet skin and tremor. Polydipsia, dysphagia, vomiting, and pruritus were reported as first symptoms extremely rarely. Twenty-six per cent (10/39) of pubertal girls reported irregular menses (Table 1).

### Table 1. Clinical and biochemical findings at diagnosis (SDG)

| Age at diagnosis | Median | Range |
|------------------|--------|-------|
| Entire group     | 14.96 years | 3.3-17.5 |
| Girls            | 14.92 years | 2.7-17.5 |
| Boys             | 14.92 years | 5.4-17.4 |

| Complaints    | n (%) |
|---------------|-------|
| Fine, wet skin | 42 (70) |
| Tremor        | 32 (53) |
| Weight loss   | 29 (48) |
| Heat intolerance | 30 (50) |
| Shorten attention span | 22 (37) |
| Muscle weakness | 21 (35) |
| Fatigability   | 21 (35) |
| Restlessness   | 21 (35) |
| Irritability   | 17 (28) |
| Sleep disturbances | 18 (30) |
| Hair loss      | 10 (17) |
| Frequent stooling | 6 (10) |
| Hyperhidrosis  | 5 (8) |
| Increased appetite | 4 (7) |

| Signs          | n (%) |
|----------------|-------|
| Tachycardia    | 55 (92) |
| Palpable goitre| 51 (85) |
| Bruit over thyroid | 18 (30) |
| TAO            | 16 (27) |

| Laboratory findings | n (%) |
|---------------------|-------|
| Elevated liver enzymes | 28 (47) |
| Leucopaenia         | 5 (8) |
| Decreased cholesterol level | 12 (20) |
| Decreased triglyceride level | 4 (7) |

| Other abnormalities | n (%) |
|---------------------|-------|
| Increased blood flow in USG | 48 (80) |
| Cardiac arrhythmia   | 5 (8) |

| Comorbidities     | n (%) |
|-------------------|-------|
| Allergic disease  | 10 (17) |
| Other autoimmune disease | 5 (8) |
| Genetic disorder  | 2 (3) |

### Fig. 1. Incidence rate in particular months of the year in children with Graves’ disease
102.90 IU/ml (range 1.2-3488 IU/ml) and 226.55 IU/ml (range 0.2-6656 IU/ml), respectively.

**Evaluation of treatment and side effects**

The majority of SDG patients (n = 59) were treated with methimazole (MMI), only one patient received propylthiouracil (PTU) as initial therapy. Adverse drug reactions occurred in 13 patients (21.67%); hive (n = 3), pruritus (n = 1), leucopaenia (n = 4), elevated liver enzymes (n = 4), and purpuric skin lesions (n = 1). Thirty-two children (53%) developed hypothyroidism during the first course of ATD treatment and simultaneously received supplementation with L-thyroxin.

Remission was defined as being euthyroid for one year after cessation of therapy [2]. Relapse was defined as recurrence of hyperthyroidism at any time during the treatment or after withdrawal of thyrostatics.

In 56 children under observation longer than three months after starting ATD treatment, prolonged TSH suppression (> 3 months) was found in 18 (32%) patients. In 31 children observed ≥ 24 months, relapses after first-line treatment occurred in 10 patients (32%), and relapses after completion of antithyroid drug therapy occurred in six patients (19%). In children observed < 24 months (n = 29) relapses after first-line treatment were found in 14 patients (48%). Ten patients were referred for radioiodine therapy, and one patient was qualified for strumectomy.

**Comparison of medical data of patients diagnosed with Graves’ disease in two decades**

| Parameter | FDG 1998-2007 | SDG 2008-2017 | p-value |
|-----------|---------------|---------------|---------|
| n (%)     | 34 (100)      | 60 (100)      | –       |
| Girls     | 28 (82.4)     | 52 (86.67)    | NS      |
| Boys      | 6 (17.7)      | 8 (13.33)     | –       |
| Mean age  | 11.7 ye (6.4-16.4) | 13.7 ye (3.3-17.5) | NS      |
| Positive family history of thyroid disease | 13 (38) | 18 (30) | NS |
| Positive family history of Graves’ disease | 10 (29) | 4 (7) | 0.004* |
| Other autoimmune disease | 4 (11.7) | 5 (8.5) | NS |
| Disorders with predisposition to autoimmune disease | Down syndrome: 3 (9) | Down syndrome: 1 (1.7) |
| Allergic disease | 8 (23.5) | 12 (20) | NS |
| Mean TRAb value | 8.87 IU/l (3.6-19 IU/l) | 12.23 IU/l (2.46-40 IU/l) | NS |
| Presence of TAO | 15 (44) | 17 (28.3) | NS, 0.11 |
| Side effects of ATDs | 6 (17) | 13 (21.67) | NS |
| Severe side effects of ATDs | 3 (8.5) | 0 | 0.02* |

Table 2. Percentage of positive anti-thyroid antibodies in SDG children

| Parameter | n | % |
|-----------|---|---|
| Positive TRAb | 60 | 100 |
| Positive anti-TGAb and/or anti-TPOAb | 56 | 93 |

TRAb – TSH receptor antibodies; anti-TGAb – anti-thyroglobulin antibodies, anti-TPOAb – anti-thyroid peroxidase

followed implementation of iodine prophylaxis programme

In our centre there were 34 newly diagnosed patients in FDG and 60 patients in SDG. No statistically significant difference in the mean age and sex contribution at diagnosis between groups was found. Familial prevalence of GD was significantly more frequent in FDG than in SDG (29% vs. 7%; p = 0.004). The mean value of TRAb was higher in SDG, but no statistical significance was found (p > 0.05). Occurrence of thyroid autoimmune ophthalmopathy (TAO) in the second decade decreased (44% vs. 28.3%); however, the difference was not statistically significant (p > 0.05). Severe side effects of ATDs were observed significantly more often in FDG than in SDG (p < 0.05). All other clinical features of GD between FDG and SDG did not differ significantly (Table 3).

**Discussion**

In our study, the two-fold higher number of patients in SDG suggests increasing incidence of GD in children in the last 10 years. However, the study was a single-centre
The next finding was significantly more frequent familial observation, hence it does not have epidemiological value.

Reports suggest a conversion of GD to HT [22, 23] and hypothyroidism rather than classical GD. What is more, recently some pathogenesis of hyperthyroidism in these patients is similar against TSH receptor but also involved other thyroid antibodies. In our patients with GD were primarily not only directed to the receptor but also involved other thyroid antigens at the onset of the disease. This may indicate that the pathogenesis of hyperthyroidism in these patients is similar to HT, and it could be named autoimmune hyperthyroidism rather than classical GD. What is more, recently some reports suggest a conversion of GD to HT [22, 23] and vice versa [24].

TAO occurs in one third of children with GD [25]. It occurs more frequent in female and post-pubertal patients [26, 27]. In our study a decreasing prevalence of TAO was observed in SDG, but the difference was not statistically significant (p = 0.11). However, this beneficial tendency might be connected with the decreasing popularity of smoking in Poland reported in recent years and decreased exposure to passive nicotinism in public areas [28]. Smoking has been proven as one of the strongest risk factors of TAO [29, 30].

In children, the recommended initial treatment of choice is antithyroid drug therapy with methimazole (MMI). Propylthiouracil (PTU) should not be prescribed in paediatric patients due to reports of PTU-induced ANCA-positive vasculitis and rapidly progressive PTU liver failure with a low chance of reversibility. In contrast, MMI is not associated with severe liver failure in children [31] or with high prevalence of MPO-ANCA [32]. Adverse events during MMI therapy are dose-dependent and affect up to 20% of children [33]. In our study, side effects of ATDs were reported by 17% to 21.7% of children in FDG and SDG, respectively. We observed significantly less frequent severe adverse drug events in SDG (p < 0.05). Probably this is connected with decreased use of PTU in recent years. In SDG only one patient was treated with PTU; in FDG more patients received PTU as initial treatment, and more severe effects were reported in that group. Many studies support the observation that pharmacological treatment of GD in children is not very effective [34]. It allows long-term remission only in 30% of patients [35, 36]. One of the most important relapse risk factors is lack of TSH normalisation during the first three months of treatment [37, 38]. In our study among SDG patients prolonged TSH suppression was found in 32% of children. The same percentage of children treated ≥ 24 months had relapses after first-line treatment. However, prolonged TSH suppression highlights a low chance of remission and can indicate candidate patients requiring definitive therapy in the future.

Our paper supports other authors’ data regarding the seasonality of new diagnosis of GD with increased incidence from the end of spring to the end of autumn [37]. The hypotheses explaining this phenomenon include viral infections [37], allergic sensitisation [38], and decreased vitamin D concentration [39]. Seasonality is also observed in relapses of GD after completion of anti-thyroid drug therapy, with higher rates in spring and summer in comparison to autumn and winter [40].

Conclusions

We realise that our study has some limitations because of its retrospective character. We analysed medical records that were not originally designed for the study. Nevertheless, we can conclude that:
In our study, after mandatory salt iodination, a tendency of an increase in newly diagnosed GD in children without family susceptibility was observed.

The antibody profile in our group of GD children indicates the significant contribution of autoimmune processes involving all thyroid antigens; therefore, the term “autoimmune hyperthyroidism” seems to be more appropriate than classical GD in this group of patients.

The first-choice treatment with MMI rarely causes adverse events during the therapy, and they have benign character.

The authors declare no conflict of interest.

References

1. Lavard L, Ranlov I, Perrild H, et al. (1994): Incidence of juvenile thyrotoxicosis in Denmark, 1982-1988. A nationwide study. Eur J Endocrinol 130: 565-568.
2. Ross DS, Burch HB, Cooper DS, et al. (2016): American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and other causes of Thyrotoxicosis. Thyroid 26: 1343-1421.
3. Goday-Arno A, Cerda-Esteva M, Flores-Le-Roux JA, et al. (2008): Hyperthyroidism in a population with Down syndrome (DS). Clin Endocrinol (Oxf) 71: 110-114.
4. De Luca F, Corrias A, Salerno M, et al. (2010): Peculiarities of Graves’ disease in children and adolescents with Down’s syndrome. Eur J Endocrinol 162: 591-595.
5. Wasniewska M, Corrias A, Messina MF, et al. (2010): Graves’ disease prevalence in a young population with Turner syndrome. J Endocrinol Invest 33: 69-70.
6. Brown JJ, Datta V, Browning MJ, Swift PG (2004): Graves’ disease in DiGeorge syndrome: patient report with a review of endocrine autoimmunity associated with 22q11.2 deletion. J Pediatr Endocrinol Metab 17: 1575-1579.
7. Luo Y, Kawashima A, Ishido Y, et al. (2014): Iodine Excess as an Environmental Risk Factor for Autoimmune Thyroid Disease. Int J Mol Sci 15: 12895-12912.
8. Vučinić M, Kušec V, Dundović S, et al. (2018): The effect of 17 years of increased salt iodization on the prevalence and nature of goiter in Croatian schoolchildren. J Pediatr Endocrinol Metab Jul 28. pii: jjem.ahead-of-print/jjem-2018-0129/ jem-2018-0129. doi: 10.1515/jjem-2018-0129.
9. Zois C, Stavrou I, Kalogera C, et al. (2003): High Prevalence of Autoimmune Thyroiditis in Schoolchildren After Elimination of Iodine Deficiency in Northwestern Greece. Thyroid 13: 485-489.
10. Fernando RF, Chandrasinge PC, Pathmeswaran AA (2012): The prevalence of autoimmune thyroiditis after universal salt iodisation in Sri Lanka. Ceylon Med J 57: 116-119.
11. Būlow Pedersen I, Laurberg P, Knudsen N, et al. (2006): Increase in Incidence of Hyperthyroidism Predominantly Occurs in Young People after Iodine Fortification of Salt in Denmark. J Clin Endocrinol Metab 91: 3830-3834.
12. Zarządzenie Ministra Zdrowia i Opieki Społecznej z dnia 24 lipca 1996 roku w sprawie zakazu produkcji i wprowadzania do obrotu w celach spożywczych niektórych rodzajów soli. http://www.monitorpolski.gov.pl/mp/1996/s/48/462 (pol).
13. Szybiński Z (2009): Iodine prophylaxis in Poland in the lights of the WHO recommendation on reduction of the daily salt intake. Pediatr Endocrinol Diabetes Metab 15: 103-107.
14. Kucharska A, Wzrosek A, Franas, Izabela A, et al. (2006): The factors determining the effectiveness of antithyroid drug therapy of Graves’ disease in children. Pediatr Endocrinol 4: 15-21.
15. Słowińska-Klencka D, Klenczi M, Sportunity, Lewiński A (2002): Fine-needle aspiration biopsy of the thyroid in an area of endemic goitre: influence of restored sufficient iodine supplementation on the clinical significance of cytological results. Eur J Endocrinol 146: 19-26.
16. Doufas AG, Mastorakos G, Chatziioannou S, et al. (1999): The predominant form of non-toxic goiter in Greece is now autoimmune thyroiditis. Eur J Endocrinol 140: 505-511.
17. Harach HR, Williams ED (1995): Thyroid cancer and thyroiditis in the goitrous region of Salta, Argentina, before and after prophylactic iodine. Clin Endocrinol (Oxf) 43: 701-706.
18. Rasooly L, Burek CL, Rose NR (1996): Iodine-induced autoimmune thyroiditis in NOD-H-2b4 mice. Clin Immunol Immunopathol 81: 287-292.
19. Būlow Pedersen I, Knudsen N, Carle A, et al. (2011): A cautious iodization program bringing iodine intake to a low recommended level is associated with an increase in the prevalence of thyroid autoantibodies in the population. Clin Endocrinol (Oxf) 75: 120-126.
20. Ogawa T, Sakata S, Nakamura S, et al. (1994): Thyroid hormone autoantibodies in patients with Graves’ disease: effect of anti-thyroid drug treatment. Clin Chim Acta 228: 113-122.
21. Mariotti S, Catagrel P, Piccolo P, et al. (1990): Antithyroid peroxidase autoantibodies in thyroid diseases. J Clin Endocrinol Metabol 71: 661-669.
22. Umar H, Muallina N, Adam JM, Sanusi H (2006): Hashimoto’s thyroiditis following Graves’ disease. Acta Med Indones 42: 31-35.
23. Ohye H, Nishihara E, Sasaki I, et al. (2006): Four cases of Graves’ disease which developed after painful Hashimoto’s thyroiditis. Intern Med 45: 385-389.
24. Pak S, Valencia D, Fershko A (2017): Transformation of Hashimoto thyroiditis to Graves’ disease. Res Rev Insights. doi: 10.15761/RRI.1000117.
25. Krassas GE, Segni M Wiersinga WM (2004): Childhood Graves’ ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 153: 515-520.
26. Acuna OM, Athannassaki I, Paysse EA (2007): Association between thyroid-stimulating immunoglobulin levels and ocular findings in pediatric patients with Graves’ disease. Trans Am Ophthalmol Soc 105: 146-150; discussion: 150-151.
27. Lazar L, Kalter-Leibovic O, Pertzelan A, et al. (2000): Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 85: 3678-3682.
28. Główny Urząd Statystyczny. Zdrowie i zachowania zdrowotne Polaków w świetle badania EHIS 2014. https://stat.gov.pl/obszary-tematyczne/zdrowie/zdrowie-i-zachowania-zdrowotne-polski-w-swiece-badania-ehis-2014-101.html (pol).
29. Villanueva R, Inzerillo AM, Tomer Y, et al. (2000): Limited Genetic Susceptibility to Severe Graves’ Ophthalmopathy: No Role for CTLA-4 But Evidence for an Environmental Etiology. Thyroid 10: 791-798.
30. Hegediüs L, Brix TH, Vestergaard PJ (2004): Relationship between cigarette smoking and Graves' ophthalmopathy. Endocrinol Invest 27: 265-271.
31. Rivkees SA, Mattison DR (2009): Propylthiouracil (PTU) Hepatotoxicity in Children and Recommendations for Discontinuation of Use. Int J Pediatr Endocrinol 2009: 132041. doi: 10.1155/2009/132041.
32. Sato H, Hattori M, Fujieda M, et al. (2000): High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 85: 4270-4273.
33. Rivkees SA, Stephenson K, Dinauer C (2010): Adverse events associated with methimazole therapy of Graves' disease in children. Int J Pediatr Endocrinol 2010: 176970. doi: 10.1155/2010/176970.
34. John M, Sundrarajan R, Gomadam SS (2015): Anti-thyroid drugs in pediatric Graves' disease. Indian J Endocrinol Metab 19: 340-346.
35. Kaguelidou F, Alberti C, Castanet M, et al. (2008): Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 93: 3817-3826.
36. Glaser NS, Styne DM (1997): Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 82: 1719-1726.
37. Dong YH, Fu DG (2014): Autoimmune thyroid disease: mechanism, genetics and current knowledge. Eur Rev Med Pharmacol Sci 18: 3611-3618.
38. Nagata K, Kumata K, Nakayama Y, et al. (2017): Epstein-Barr Virus Lytic Reactivation Activates B Cells Polyclonally and Induces Activation-Induced Cytidine Deaminase Expression: A Mechanism Underlying Autoimmunity and Its Contribution to Graves' Disease. Viral Immunol 30: 240-249.
39. Xu MY, Cao B, Yin J, et al. (2015): Vitamin D and Graves' disease: a meta-analysis update. Nutrients 7: 3813-3817.
40. Misaki T, Iida T, Kasagi K, Konishi J (2003): Seasonal variation in relapse rate of Graves' disease after thionamide drug treatment. Endocr J 50: 669-672.